KENILWORTH, N.J.--(BUSINESS WIRE)--With adverse drug events (ADEs) triggering an estimated 700,000 ED visits and 120,000 hospitalizations, RDx BioScience (RDx) points ...
Pharmacogenomics (PGx) is a foundational component of precision medicine, yet many laboratories and health systems continue to face challenges translating PGx evidence into routine clinical workflows.
Prostate cancer (PC) is a significant health concern, being the second leading cause of death among American men. The standard treatment for advanced PC often involves androgen deprivation therapy ...
Expert Rev Mol Diagn. 2012;12(8):841-855. From their experience with PGx testing, the authors believe that this clinical utility in primary care is possible. For instance, the authors recently ...
Pharmacogenomics (PGx) testing is a powerful tool in the evolution of personalized medicine. However, for its full potential to be realized, labs must do more than just offer a scientifically sound ...
STONY BROOK, NY / ACCESSWIRE / June 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that the New York ...
Have you ever wondered why certain medications don’t seem to work as well for you as they do for others? This variability in drug response is what pharmacogenomic testing hopes to explain by looking ...
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Genomind ®, a leading mental health care company, is launching on August 10, 2019 Genomind Professional PGx Expressā„¢, a new, more focused report and set of ...
Prostate cancer (PC) is a significant health concern, being the second leading cause of death among American men. The standard treatment for advanced PC often involves androgen deprivation therapy ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
STONY BROOK, NY / ACCESSWIRE / June 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a global leader in PCR-based DNA technologies, today announced that its molecular diagnostics ...